Creo Medical Group (LON:CREO) Issues Earnings Results

Creo Medical Group (LON:CREO) released its quarterly earnings data on Wednesday. The company reported GBX (2) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Creo Medical Group had a negative net margin of 268.57% and a negative return on equity of 38.29%.

Creo Medical Group Price Performance

CREO stock traded down GBX 0.60 during trading on Thursday, hitting GBX 9.80. 2,447,721 shares of the company’s stock traded hands, compared to its average volume of 791,934. Creo Medical Group has a 52 week low of GBX 9.50 and a 52 week high of GBX 18.50. The stock has a market capitalization of £47.61 million, a price-to-earnings ratio of 9.80 and a beta of 1.56. The business has a fifty day simple moving average of GBX 12.62 and a 200 day simple moving average of GBX 12.82. The company has a debt-to-equity ratio of 8.09, a quick ratio of 2.19 and a current ratio of 2.79.

Analyst Ratings Changes

Separately, Shore Capital Group reiterated a “house stock” rating and issued a GBX 40 price target on shares of Creo Medical Group in a report on Thursday, July 23rd.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.